Oct 15, 2026, 8:00 AM EDT · 19 days ago Daxor Accelerates Commercial Expansion of Next-Gen Blood Volume Diagnostic Platform at MedAxiom CV Transforum Fall '26
Oct 14, 2026, 8:00 AM EDT · 20 days ago Daxor Announces Strong Commercial Interest and New Clinical Data at HFSA 2026
Oct 13, 2026, 8:00 AM EDT · 21 days ago Daxor to Showcase Blood Volume Analysis Platform at ASN Kidney Week 2026
Oct 1, 2026, 8:00 AM EDT · 4 weeks ago Daxor to Showcase Next-Gen Blood Volume Analyzer and New Clinical Data at HFSA 2026
Sep 8, 2026, 5:40 PM EDT · 7 weeks ago Daxor Corporation to Participate in the 10th Annual Lake Street Best Ideas Growth Conference
Sep 1, 2026, 8:00 AM EDT · 2 months ago Daxor Corporation CEO and President Michael Feldschuh Delivers 1st Half Corporate Update in Shareholder Letter
Jul 29, 2026, 10:40 PM EDT · 3 months ago Daxor Broadens Outpatient Footprint with Initiation of ezBVA Lab Diagnostic Services in Kansas
Jul 7, 2026, 8:00 AM EDT · 3 months ago Daxor Corporation Announces First-Time Exhibition at the 14th Annual Dysautonomia International Conference in The Woodlands, Texas
2026-06-02T13:08:30.000Z · 5 months ago Daxor issued patent from USPTO for absolute blood volume monitoring
Jun 2, 2026, 8:00 AM EDT · 5 months ago Daxor Corporation Receives U.S. Patent for Breakthrough Remote Blood Volume Monitor
Apr 28, 2026, 8:00 AM EDT · 6 months ago Daxor Leverages MedAxiom CV Transforum Spring'26 to Accelerate Commercial Adoption of Blood Volume Analysis
Apr 8, 2026, 8:00 AM EDT · 6 months ago Daxor Expands Customer Footprint with New BVA Program at High-Volume Ohio Cardiology Center
Mar 26, 2026, 8:00 AM EDT · 7 months ago Daxor's Blood Volume Analysis Metric Validated as Uniquely Accurate Versus Capillary Leak Indexes in New Clinical Data Presented at SCCM 2026
Mar 17, 2026, 8:00 AM EDT · 7 months ago Daxor Corporation to Showcase Next-Generation Portable Blood Volume Analyzer at ACC.26; Highlighting Clinical Outcomes and Reduced Readmissions
2026-03-10T12:37:53.000Z · 7 months ago Daxor to debut portable blood volume analyzer at SCCM Critical Care Congress
Mar 10, 2026, 8:00 AM EDT · 7 months ago Daxor to Debut New Rapid, Portable Blood Volume Analyzer at SCCM 2026 Critical Care Congress
Mar 9, 2026, 8:00 AM EDT · 7 months ago Daxor Corporation to Participate in the iAccess Virtual Alpha Best Ideas Spring Investment Conference 2026
Mar 3, 2026, 8:00 AM EST · 8 months ago Daxor Corporation Reports 2025 Fiscal Year Results: Operating Revenue Up 45%, Net Asset Value Rises to $9.07 Per Share
2026-02-24T13:10:30.000Z · 8 months ago Daxor continues strategic expansion, opens new BVA program in Tennessee
Feb 24, 2026, 8:00 AM EST · 8 months ago Daxor Scales Outpatient Presence; Launches BVA Diagnostic Program in Tennessee
2026-02-10T13:21:00.000Z · 8 months ago Daxor to transition to Securities Exchange Act of 1934 reporting company
2026-01-23T13:11:18.000Z · 9 months ago Daxor prices 765,958 shares at $11.75 in registered direct offering
Jan 23, 2026, 8:00 AM EST · 9 months ago Daxor Corporation Announces $9 Million Registered Direct Offering
2025-11-25T13:05:48.000Z · 11 months ago Daxor announces expansion of its BVA platform into three new facilities
Nov 25, 2025, 8:00 AM EST · 11 months ago Daxor Fuels Growth with Three New Facility Adoptions and Deployment of Next-Generation BVA Analyzer
Oct 21, 2025, 8:00 AM EDT · 1 year ago Daxor CEO Michael Feldschuh to Engage Investors at Exclusive Maxim Growth Summit
2025-10-15T12:15:43.000Z · 1 year ago Daxor to exhibit at the MedAxiom CV Transforum Fall’25 Conference
Sep 30, 2025, 8:00 AM EDT · 1 year ago Daxor Unveils New FDA-Cleared BVA Analyzer Amid Strong Market Demand and Pivotal Clinical Data at HFSA
Sep 23, 2025, 8:00 AM EDT · 1 year ago Daxor Corporation Unveils Breakthrough Next-Gen BVA Analyzer at HFSA Annual Scientific Meeting
2025-09-04T12:10:58.000Z · 1 year ago Daxor’s blood volume analysis validated for COVID, sepsis patients
Sep 4, 2025, 8:00 AM EDT · 1 year ago Daxor's Blood Volume Analysis Validated for COVID and Sepsis Patients in New Peer-Reviewed Pilot Study Published in the Journal of Critical Care
Sep 3, 2025, 8:00 AM EDT · 1 year ago Daxor Corporation to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Aug 7, 2025, 7:55 AM EDT · 1 year ago Daxor Corporation Receives FDA Clearance for New Rapid, Lightweight, Blood Volume Analysis System
Jul 22, 2025, 8:00 AM EDT · 1 year ago Daxor's Blood Volume Analysis Technology Accelerates Market Penetration with Three New Facility Adoptions
May 14, 2025, 8:00 AM EDT · 1 year ago Daxor Announces Duke University Study on Blood Volume Analysis in Heart Failure Published in American Heart Journal
May 13, 2025, 8:00 AM EDT · 1 year ago Daxor's Blood Volume Analysis Diagnostic Reaches Two New U.S. Healthcare Systems
May 7, 2025, 8:00 AM EDT · 1 year ago Florida Healthcare Leader Embraces Daxor Blood Volume Analysis Technology
May 6, 2025, 8:00 AM EDT · 1 year ago Three New Medical Centers Adopt Daxor's Blood Volume Diagnostic Signaling Growing Clinical Acceptance
Apr 22, 2025, 8:00 AM EDT · 1 year ago Daxor Corporation to Exhibit at the 45th International Society for Heart and Lung Transplant (ISHLT) Annual Meeting and Scientific Sessions
Apr 17, 2025, 8:00 AM EDT · 1 year ago Daxor Corporation to Showcase Innovative Blood Volume Analysis at MedAxiom Cardiovascular Transforum Spring 2025
Apr 15, 2025, 8:00 AM EDT · 1 year ago New Research at ACC25 Shows Daxor BVA-Identified Euvolemic Heart Failure Patients Experience 2.61 Times Better Survival
Apr 2, 2025, 8:00 AM EDT · 1 year ago Daxor Corporation Announces New Data from Duke University and Highlights Key BVA Insights at American College of Cardiology's 74th Annual Scientific Session and Expo
Mar 28, 2025, 8:00 AM EDT · 1 year ago Daxor Expands Blood Volume Analysis Technology Across Midwest, Wisconsin, and New Jersey Healthcare Networks
Mar 4, 2025, 4:55 PM EST · 1 year ago Daxor Corporation Reports Increase in NAV to $7.25 Per Share and 116.5 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2024
Mar 4, 2025, 3:53 PM EST · 1 year ago Daxor Corporation to Host Investor Conference Call to Discuss Fiscal Year 2024 Financial Results and Provide a Corporate Update on March 6, 2025
Mar 4, 2025, 9:00 AM EST · 1 year ago Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders
Mar 4, 2025, 8:00 AM EST · 1 year ago Daxor Corporation Reports Increase in NAV to $7.25 Per Share and 116.5 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2023
Feb 28, 2025, 8:00 AM EST · 1 year ago Daxor Expands Blood Volume Analysis Services at Major Midwest Healthcare Center
Feb 27, 2025, 8:00 AM EST · 1 year ago Daxor Corporation Expands Blood Volume Analysis Technology to Major New Jersey Hospitals
Feb 19, 2025, 8:00 AM EST · 1 year ago Daxor Corporation Announces New Data on Blood Volume Analysis from Duke and Yale Universities Presented at THT 2025
Feb 18, 2025, 10:50 AM EST · 1 year ago TruLite Health Bolsters Health Equity Expertise with Expanded Leadership Team ARDT
Feb 14, 2025, 8:00 AM EST · 1 year ago Daxor's Blood Volume Analysis Uncovers Hidden Heart Failure Subtype in Nearly 1 in 5 Patients, Enabling Targeted Treatment
Feb 13, 2025, 8:00 AM EST · 1 year ago New Multicenter Study Highlights Utility of Daxor's Blood Volume Analysis in Heart Failure Care
Dec 18, 2024, 8:00 AM EST · 1 year ago Daxor Expands Its BVA-100™ Blood Volume Diagnostic to Two New Hospital Systems Adding to Sales Momentum
Oct 9, 2024, 8:00 AM EDT · 2 years ago DAXOR'S INNOVATIVE BVA-100™ BLOOD VOLUME DIAGNOSTIC FEATURED AT MEDAXIOM CV TRANSFORUM FALL '24
Oct 8, 2024, 8:00 AM EDT · 2 years ago Daxor Corporation to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit
Sep 27, 2024, 5:00 PM EDT · 2 years ago Daxor Corporation Streamlines Regulatory Strategy for Groundbreaking Diagnostic Device